Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,099 public trials 2,041 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

NCT01568866

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Providence St. Joseph Medical Center Burbank, California, United States
  • UCSD Moore Cancer Center La Jolla, California, United States
  • UCLA Medical Center Los Angeles, California, United States
  • Central Coast Medical Oncology Group Santa Maria, California, United States
View all 241 locations
View Trial Details
Completed

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

NCT02257567

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Univ of Colorado Canc Ctr Aurora, Colorado, United States
View all 62 locations
View Trial Details
Completed

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

NCT01345019

Conditions
Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, +34 more
Locations
  • Research Site Tucson, Arizona, United States
  • Research Site Fayetteville, Arkansas, United States
  • Research Site Anaheim, California, United States
  • Research Site Campbell, California, United States
View all 309 locations
View Trial Details
Completed

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

NCT02572167

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Stanford Cancer Center Stanford, California, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Karmanos Cancer Institute / Wayne State University Detroit, Michigan, United States
View all 13 locations
View Trial Details

Related conditions